Abstract: To observe the expression levels of metastasis-associated proteins in prostate carcinoma and cell lines with different potencies for bone metastasis. Such proteins include P63, CXCR-4, and MMP-2. Methods: The expression levels of P63, CXCR-4, and MMP-2 were studied using immunohistochemistry and Western blot assays in 60 cases of prostate cancer. Among these cases, 30 involved osseous metastasis and the other 30 did not. Two kinds of human prostate cancer cell lines with different potencies for bone metastasis, namely, PC-3 and PC-3M1E8, were investigated. Results: The positive expression rates of CXCR-4 and MMP-2 were 33.3% and 40.0%, respectively, in the non-bone-metastasis group. The rates were 73.3% and 66.7%, respectively, in the bone-metastasis group. The rates of P63 in the non-bone- and bone-metastasis groups were 76.7% and 20.0%, respectively. P63 was detected with a high level of expression in PC-3, which had a low metastatic potential. However, P63 was absent in PC-3M1E8, which had a high metastatic potential. CXCR-4 and MMP-2 exhibited completely opposite expression behaviors from P63 in the two cell lines. The average grey levels of P63, CXCR-4, and MMP-2 in PC-3 and PC-3M1E8 were (1.74 ± 0.32) vs. 0, 0 vs. (1.98 ± 0.16), and 0 vs. (2.31 ± 0.26), respectively. Conclusion: The expression levels of the metastasis-associated proteins P63, CXCR-4, and MMP-2 may be useful markers to evaluate the biological behaviors and prognosis of prostate cancer.